Singapore markets close in 4 hours 49 minutes

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.46-0.67 (-5.52%)
At close: 04:00PM EDT
11.46 0.00 (0.00%)
After hours: 04:20PM EDT

Phathom Pharmaceuticals, Inc.

100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees452

Key executives

NameTitlePayExercisedYear born
Ms. Terrie J. CurranPresident, CEO & Director1.22MN/A1969
Mr. David A. SocksCo-Founder & Director54.17kN/A1975
Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder & COO888.9kN/A1960
Ms. Molly Henderson CPA, MBAChief Financial & Business Officer777.76kN/A1971
Dr. Aditya Kohli Ph.D.Co-Founder319.65kN/A1988
Mr. Paul CocjaChief People OfficerN/AN/AN/A
Mr. Tom HarrisChief Development Sciences OfficerN/AN/AN/A
Dr. Eckhard Leifke M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Martin J. GilliganChief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Corporate governance

Phathom Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.